A research team discovers a novel bacterial toxin that causes severe hypotension in infected patients. In vitro studies show the toxin ADP-ribosylates a specific amino acid on Gq alpha subunits, preventing their activation by GPCRs. Patients develop hypotension despite elevated levels of vasopressin, angiotensin II, and endothelin-1. Synthesize the pathophysiological mechanism explaining why multiple vasopressor hormones fail to maintain blood pressure in these patients.
Q2
A 42-year-old woman with metastatic melanoma develops severe colitis while being treated with ipilimumab (anti-CTLA-4 antibody) and nivolumab (anti-PD-1 antibody). Her oncologist must decide whether to continue immunotherapy or treat the colitis with immunosuppression. Tumor analysis shows high PD-L1 expression and BRAF wild-type status. Previous conventional chemotherapy failed. Evaluate the optimal management strategy considering signal transduction implications.
Q3
A 35-year-old man with familial adenomatous polyposis (FAP) undergoes genetic counseling. He has a germline APC mutation and asks about cancer risk for his children. His physician explains that APC normally regulates beta-catenin levels. Evaluate which downstream transcriptional consequence most directly results from loss of functional APC protein in colonic epithelial cells.
Q4
A 58-year-old woman with HER2-positive metastatic breast cancer initially responds to trastuzumab (anti-HER2 antibody) but develops resistance after 18 months. Tumor analysis reveals increased expression of HER3 and continued PI3K/AKT pathway activation despite HER2 blockade. Analyze the mechanism underlying this adaptive resistance.
Q5
A 4-year-old boy presents with recurrent bacterial infections, eczema, and elevated IgE levels. Flow cytometry shows absent expression of Wiskott-Aldrich syndrome protein (WASP) in his leukocytes. His T cells show impaired responses to T-cell receptor stimulation. Analyze the mechanism by which absent WASP impairs T-cell receptor signaling and cellular function.
Signal transduction pathways US Medical PG Practice Questions and MCQs
Question 1: A research team discovers a novel bacterial toxin that causes severe hypotension in infected patients. In vitro studies show the toxin ADP-ribosylates a specific amino acid on Gq alpha subunits, preventing their activation by GPCRs. Patients develop hypotension despite elevated levels of vasopressin, angiotensin II, and endothelin-1. Synthesize the pathophysiological mechanism explaining why multiple vasopressor hormones fail to maintain blood pressure in these patients.
A. The toxin depletes intracellular ATP preventing myosin-actin interaction
B. The toxin prevents receptor binding of vasopressor hormones through allosteric inhibition
C. ADP-ribosylation of Gq prevents PLC activation, blocking IP3-mediated calcium release and vascular smooth muscle contraction (Correct Answer)
D. ADP-ribosylation increases cAMP levels causing smooth muscle relaxation
E. The toxin activates Gi proteins causing excessive vasodilation that overwhelms vasoconstrictor signals
Explanation: ***ADP-ribosylation of Gq prevents PLC activation, blocking IP3-mediated calcium release and vascular smooth muscle contraction***
- Vasopressor hormones like **Vasopressin**, **Angiotensin II**, and **Endothelin-1** signal through **Gq-coupled receptors** to trigger **vascular smooth muscle contraction**.
- By ADP-ribosylating the **Gq alpha subunit**, the toxin inhibits **Phospholipase C (PLC)**, preventing the generation of **IP3 and DAG**, which are essential for releasing **intracellular calcium**.
*The toxin prevents receptor binding of vasopressor hormones through allosteric inhibition*
- The toxin targets the **G-protein (intracellular)** rather than the **extracellular binding site** of the G-protein coupled receptors (GPCRs).
- Since binding still occurs but **signal transduction** is blocked, this describes a post-receptor defect rather than **allosteric inhibition** of the receptor itself.
*The toxin activates Gi proteins causing excessive vasodilation that overwhelms vasoconstrictor signals*
- The prompt explicitly states the toxin modifies the **Gq alpha subunit**, not the **Gi subunit**.
- **Gi protein** activation primarily lowers **cAMP**, whereas the failure of pressors in this case is linked to the lack of **calcium mobilization** via Gq.
*ADP-ribosylation increases cAMP levels causing smooth muscle relaxation*
- Increased **cAMP** (via Gs activation or Gi inhibition) does cause relaxation, but this mechanism is associated with toxins like **Cholera** or **Pertussis**.
- The modification of **Gq** specifically disrupts the **phosphoinositol pathway**, not the **adenylyl cyclase** pathway that regulates cAMP.
*The toxin depletes intracellular ATP preventing myosin-actin interaction*
- ADP-ribosylation is a specific **post-translational modification** using **NAD+** as a substrate, which does not result in systemic **ATP depletion**.
- The failure of contraction is due to a lack of **calcium-calmodulin** activation of **Myosin Light Chain Kinase (MLCK)**, not a lack of energy supply for the motor proteins.
Question 2: A 42-year-old woman with metastatic melanoma develops severe colitis while being treated with ipilimumab (anti-CTLA-4 antibody) and nivolumab (anti-PD-1 antibody). Her oncologist must decide whether to continue immunotherapy or treat the colitis with immunosuppression. Tumor analysis shows high PD-L1 expression and BRAF wild-type status. Previous conventional chemotherapy failed. Evaluate the optimal management strategy considering signal transduction implications.
A. Stop both drugs permanently as immune-related adverse events indicate loss of self-tolerance mechanisms
B. Continue both checkpoint inhibitors as tumor response depends on sustained T-cell receptor co-stimulation blockade
C. Discontinue ipilimumab, continue nivolumab with corticosteroids, as PD-1 pathway blockade may be sufficient given high PD-L1 expression (Correct Answer)
D. Continue both drugs but add TNF-alpha inhibitor to block inflammatory signaling without affecting anti-tumor immunity
E. Stop all immunotherapy and switch to targeted therapy despite BRAF wild-type status
Explanation: ***Discontinue ipilimumab, continue nivolumab with corticosteroids, as PD-1 pathway blockade may be sufficient given high PD-L1 expression***
- Severe colitis is a significant **immune-related adverse event (irAE)**; managing it requires **corticosteroids** to suppress the excessive T-cell response while balancing anti-tumor efficacy.
- In patients with **high PD-L1 expression**, the **PD-1 inhibitor (Nivolumab)** may provide sufficient anti-tumor signal transduction blockade alone, allowing for the discontinuation of the more toxic **anti-CTLA-4** agent.
*Continue both checkpoint inhibitors as tumor response depends on sustained T-cell receptor co-stimulation blockade*
- Sustaining treatment during severe colitis poses a high risk of **colon perforation** and death due to uncontrolled lymphocytic infiltration.
- **CTLA-4** blockade affects the priming phase in lymph nodes, and continuing it during high-grade toxicity is contraindicated by clinical safety guidelines.
*Stop all immunotherapy and switch to targeted therapy despite BRAF wild-type status*
- Targeted therapies like **BRAF and MEK inhibitors** require the **BRAF V600 mutation** to function; they are ineffective in **BRAF wild-type** status.
- Switching to these agents would leave the patient with no effective treatment for the underlying **metastatic melanoma**.
*Continue both drugs but add TNF-alpha inhibitor to block inflammatory signaling without affecting anti-tumor immunity*
- While **TNF-alpha inhibitors** like infliximab are used for refractory colitis, they are typically added only after **corticosteroids** fail to control symptoms.
- Clinical protocols mandate the suspension of the offending agents during **Grade 3/4 toxicity** to prevent further immune-mediated tissue damage.
*Stop both drugs permanently as immune-related adverse events indicate loss of self-tolerance mechanisms*
- Benefit-risk assessment often allows for the resumption of **PD-1 inhibitors** once toxicity resolves, especially if the tumor shows evidence of responding.
- **Permanent discontinuation** of all life-saving immunotherapy may not be necessary if the toxicity is managed and the clinical benefit of the **PD-1 pathway** blockade is high.
Question 3: A 35-year-old man with familial adenomatous polyposis (FAP) undergoes genetic counseling. He has a germline APC mutation and asks about cancer risk for his children. His physician explains that APC normally regulates beta-catenin levels. Evaluate which downstream transcriptional consequence most directly results from loss of functional APC protein in colonic epithelial cells.
A. Increased SMAD-mediated transcription of growth inhibitory genes
B. Decreased TCF/LEF-mediated transcription of cell cycle genes like c-MYC and cyclin D1
C. Increased p53-mediated transcription of pro-apoptotic genes
D. Decreased NF-kB transcriptional activity reducing inflammatory gene expression
E. Constitutive TCF/LEF-mediated transcription of proliferation genes due to nuclear beta-catenin accumulation (Correct Answer)
Explanation: ***Constitutive TCF/LEF-mediated transcription of proliferation genes due to nuclear beta-catenin accumulation***
- In the absence of functional **APC protein**, the destruction complex cannot phosphorylate **beta-catenin**, leading to its accumulation in the cytoplasm and subsequent translocation to the **nucleus**.
- Once in the nucleus, **beta-catenin** acts as a co-activator for **TCF/LEF transcription factors**, leading to persistent expression of oncogenes like **c-MYC** and **cyclin D1**.
*Decreased TCF/LEF-mediated transcription of cell cycle genes like c-MYC and cyclin D1*
- Loss of **APC** leads to an **increase**, rather than a decrease, in the transcriptional activity of TCF/LEF because **beta-catenin** is no longer being degraded.
- This inappropriate activation of the **Wnt signaling pathway** is what drives the formation of colonic adenomas in patients with **FAP**.
*Increased p53-mediated transcription of pro-apoptotic genes*
- **APC** mutations primarily affect the **Wnt/beta-catenin pathway**, whereas **p53** mutations typically occur later in the adenoma-carcinoma sequence.
- Loss of functional APC does not directly increase **p53-mediated apoptosis**; if anything, it provides a selective advantage for cells to bypass growth controls.
*Decreased NF-kB transcriptional activity reducing inflammatory gene expression*
- The **NF-kB pathway** is a separate signaling cascade involved in inflammation and immune response, not the primary mechanism of **APC/beta-catenin** tumorigenesis.
- APC loss specifically targets **proliferation genes** through beta-catenin stabilization, rather than reducing **NF-kB** activity.
*Increased SMAD-mediated transcription of growth inhibitory genes*
- **SMAD proteins** are downstream effectors of the **TGF-beta signaling pathway**, which typically provides growth inhibitory signals in the colon.
- Mutations in the **TGF-beta/SMAD** pathway often occur later in colon cancer progression and are distinct from the early **APC** mutation consequences.
Question 4: A 58-year-old woman with HER2-positive metastatic breast cancer initially responds to trastuzumab (anti-HER2 antibody) but develops resistance after 18 months. Tumor analysis reveals increased expression of HER3 and continued PI3K/AKT pathway activation despite HER2 blockade. Analyze the mechanism underlying this adaptive resistance.
A. HER3 activates p53 pathway bypassing the need for HER2 signaling
B. HER3 directly activates PI3K independent of HER2 through compensatory heterodimerization with other receptors (Correct Answer)
C. HER3 increases expression of drug efflux pumps removing trastuzumab from cells
D. HER3 downregulates HER2 expression eliminating the drug target
E. HER3 blocks trastuzumab binding sites on HER2 through steric hindrance
Explanation: ***HER3 directly activates PI3K independent of HER2 through compensatory heterodimerization with other receptors***
- **HER3** is a potent activator of the **PI3K/AKT pathway** because it contains multiple binding sites for the **p85 subunit of PI3K**, which allows it to maintain signaling when HER2 is blocked.
- Increased **HER3 expression** facilitates the formation of **HER2/HER3 or HER3/RTK heterodimers**, effectively bypassing trastuzumab inhibition to drive tumor cell survival and proliferation.
*HER3 increases expression of drug efflux pumps removing trastuzumab from cells*
- Trastuzumab is a **monoclonal antibody** and is not typically a substrate for **ATP-binding cassette (ABC) transporters** like P-glycoprotein, which handle small molecule drugs.
- Resistance to antibodies usually involves **signaling bypass** or altered receptor recycling rather than classic **multidrug resistance (MDR)** efflux mechanisms.
*HER3 blocks trastuzumab binding sites on HER2 through steric hindrance*
- **Trastuzumab** binds to the **extracellular domain IV** of HER2; there is no evidence that HER3 upregulation physically masks this specific epitope.
- Resistance is biochemical and functional through **downstream signaling restoration**, not a physical blockade of the antibody-receptor docking site.
*HER3 downregulates HER2 expression eliminating the drug target*
- In cases of acquired resistance, **HER2 amplification** and expression generally persist, as the tumor remains dependent on the **HER family signaling network**.
- The scenario explicitly states there is **continued PI3K/AKT activation** despite HER2 blockade, suggesting the target is still present but the pathway is being rerouted via **HER3**.
*HER3 activates p53 pathway bypassing the need for HER2 signaling*
- The **p53 pathway** is a tumor suppressor pathway that induces **apoptosis** or cell cycle arrest, whereas resistance mechanisms select for **oncogenic survival pathways**.
- HER3 upregulation specifically drives **PI3K/AKT signaling**, which actually inhibits apoptosis and counteracts the effects of p53 to promote **cell survival**.
Question 5: A 4-year-old boy presents with recurrent bacterial infections, eczema, and elevated IgE levels. Flow cytometry shows absent expression of Wiskott-Aldrich syndrome protein (WASP) in his leukocytes. His T cells show impaired responses to T-cell receptor stimulation. Analyze the mechanism by which absent WASP impairs T-cell receptor signaling and cellular function.
A. WASP prevents T-cell receptor internalization maintaining surface expression
B. WASP normally inhibits phospholipase C preventing excessive calcium signaling
C. WASP is required for actin polymerization necessary for immune synapse formation and downstream signaling (Correct Answer)
D. WASP activates adenylyl cyclase to produce cAMP for T-cell activation
E. WASP directly phosphorylates CD3 chains to initiate T-cell receptor signaling
Explanation: ***WASP is required for actin polymerization necessary for immune synapse formation and downstream signaling***
- **WASP** functions as an adapter protein that links membrane signaling to the **actin cytoskeleton** by activating the **Arp2/3 complex**.
- Absence of WASP prevents the **cytoskeletal reorganization** required to form a stable **immunological synapse**, which is essential for effective **T-cell receptor (TCR) signaling** and lymphocyte activation.
*WASP normally inhibits phospholipase C preventing excessive calcium signaling*
- **WASP** does not act as an inhibitor of **PLC-gamma**; instead, it is activated downstream of PLC-gamma following TCR stimulation.
- Calcium signaling is actually **diminished** or improperly localized in WASP deficiency due to the failure of the **signalosome** to organize correctly on the actin scaffold.
*WASP directly phosphorylates CD3 chains to initiate T-cell receptor signaling*
- Phosphorylation of **CD3 ITAMs** is performed by **Src-family kinases** like **Lck**, not by cytoskeletal adapter proteins like WASP.
- **WASP** lacks a kinase domain; it serves purely as a **scaffold and regulator** of actin dynamics rather than a primary signaling enzyme.
*WASP activates adenylyl cyclase to produce cAMP for T-cell activation*
- High levels of **cAMP** generally act as an **inhibitory** signal for T-cell activation, whereas WASP is required for stimulatory pathways.
- The activation of **adenylyl cyclase** is mediated by **G-protein coupled receptors**, whereas WASP is recruited by small GTPases like **Cdc42**.
*WASP prevents T-cell receptor internalization maintaining surface expression*
- WASP deficiency typically leads to **increased** turnover and defective transport, but the primary defect is in **actin-mediated mobility** and receptor clustering.
- The hallmark of **Wiskott-Aldrich Syndrome** is not primarily TCR density but the inability to relocate receptors into a functional **central supramolecular activation cluster (cSMAC)**.
